Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Marco Polizzi Appointed CEO of Paradigm Biopharmaceuticals Effective July 1, 2022

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Marco Polizzi possesses over 30 years of experience in the pharmaceutical industry in various commercially focused roles, including creating new divisions within branded and generic pharmaceutical businesses.

Maro Polizzi achieved outstanding sales results in these roles, forged several licenses, asset purchases, and other agreements with multiple top 10 global pharmaceutical companies and numerous other business partners, and generated significant returns for investors.

Polizzi has a proven track record that is highlighted by several successful business and product launches in the U.S. These include a new Institutional (Hospital & Specialty Markets) business unit at Sandoz, driving the growth of a $900 million P&L, as well as directing commercial functions for a product launch (Bivalirudin) that achieved $100+ million in sales in its first year.

Paradigm Chairman Paul Rennie said, “We expect that Marco’s broad expertise will lead Paradigm in attaining its strategic program objectives and increase shareholder value. Paradigm has been seeking a CEO with the skills to unlock the company’s commercial value fully. Marco brings extensive U.S. pharmaceutical experience, a pharmaceutical industry network, operational excellence, transactional expertise, product launch, and product pricing and reimbursement experience to Paradigm. We are confident that this experience will provide significant development and commercial value to Paradigm. Polizzi will be based in the United States and travel to Australia, Europe, and Asia as required.”

Marco Polizzi commented, “With my pharmaceutical experience, I believe I will make a significant contribution to the Paradigm business in the short and long term. I have had the opportunity to meet the Paradigm Board and key management personnel, and I can say that Paradigm’s business excites me. My feeling is primarily based on a potential blockbuster product, which may bring relief to the millions of people globally suffering from the pain and other debilitating effects of osteoarthritis and significantly increase shareholder returns. I look forward to meeting our shareholders in the coming months.”

The Paradigm Board thanks Dr. Donna Skerrett for her unwavering dedication and invaluable contribution to the company’s progress while serving as interim CEO. Dr. Skerrett will continue as Chief Medical Officer with a keen focus on successfully completing the global phase 3 clinical programs for Zilosul® following the FDA’s fast track designation protocol.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine